AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
Am J Translational Res 2011;3(1):28-47

Original Article
Differentially expressed miRNAs in the plasma may provide a
molecular signature for aggressive pancreatic cancer

Shadan Ali, Khaldoun Almhanna, Wei Chen, Philip A. Philip, Fazlul H. Sarkar

Department of Pathology1 and Division of Hematology/Oncology, Department of Internal Medicine, Karmanos
Cancer Institute, Wayne State University, Detroit, Michigan, MI, USA

Received: September 24, 2010; accepted: September, 2010; Epub: September, 2010; Published: January 1, 2011

Abstract: Pancreatic cancer (PC) has the poorest overall survival rate among all human cancers because of late
diagnosis and absence of screening tools. We compared the expression profile of microRNAs (miRNAs) in the
plasma of patients diagnosed with PC (n=50) with healthy volunteers (n=10). Data was further validated by
quantitative real-time PCR and cell-based assays. Thirty-seven miRNAs were down-regulated and 54 were
up-regulated in plasma from patients with PC. The expression of miR-21 was significantly higher, and the
expression of let-7 family (especially let-7d) and miR-146a was significantly lower in PC. Most interestingly, the
expression of miR-21 was correlated with worse survival, and the expression of let-7 was inversely correlated
with survival in this pilot study with mixed patient population. Moreover, we found that miR-21 family was markedly
over-expressed in chemo-resistant PC cell lines, which was consistent with the plasma data from PC patients.
Our previous studies have shown increased expression of miR-21 with concomitant loss of PTEN expression in
PC cells, which is consistent with our current findings showing the loss of three additional targets of miR-21
(PDCD4, Maspin and TPM1). These results suggest that identifying and validating the expression of miRNAs in
newly diagnosed patients could serve as potential biomarker for tumor aggressiveness, and such miRNAs could
be useful for the screening of high-risk patients, and may also serve as targets for future drug development.
(AJTR1009003).

Key words: Pancreatic cancer, miR-21, miR-221, Drug Resistance, PTEN, let-7d

Full Text  PDF

Address all correspondence to:
Fazlul H. Sarkar, PhD
Department of Pathology,
Karmanos Cancer Institute
Wayne State University School of Medicine
740 Hudson Webber Cancer Research Center,
4100 John R Street
Detroit, MI 48201
Tel: 313-576-8327
Fax: 313-576-8389
E-mail:
fsarkar@med.wayne.edu